Suppr超能文献

由于P-糖蛋白导致低渗透性化合物沿小肠的节段依赖性转运:外排转运在BCS III类药物口服吸收中的作用

Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs.

作者信息

Dahan Arik, Amidon Gordon L

机构信息

College of Pharmacy, The University of Michigan, Ann Arbor, Michigan 48109-1065, USA.

出版信息

Mol Pharm. 2009 Jan-Feb;6(1):19-28. doi: 10.1021/mp800088f.

Abstract

The purpose of this study was to investigate the role of P-gp efflux in the in vivo intestinal absorption process of BCS class III P-gp substrates, i.e. high-solubility low-permeability drugs. The in vivo permeability of two H (2)-antagonists, cimetidine and famotidine, was determined by the single-pass intestinal perfusion model in different regions of the rat small intestine, in the presence or absence of the P-gp inhibitor verapamil. The apical to basolateral (AP-BL) and the BL-AP transport of the compounds in the presence or absence of various efflux transporters inhibitors (verapamil, erythromycin, quinidine, MK-571 and fumitremorgin C) was investigated across Caco-2 cell monolayers. P-gp expression levels in the different intestinal segments were confirmed by immunoblotting. Cimetidine and famotidine exhibited segmental dependent permeability through the gut wall, with decreased P(eff) in the distal ileum in comparison to the proximal regions of the intestine. Coperfusion of verapamil with the drugs significantly increased the permeability in the ileum, while no significant change in the jejunal permeability was observed. Both drugs exhibited significantly greater BL-AP than AP-BL Caco-2 permeability, indicative of net mucosal secretion. Concentration dependent decrease of this secretion was obtained by the P-gp inhibitors verapamil, erythromycin and quinidine, while no effect was evident by the MRP2 inhibitor MK-571 and the BCRP inhibitor FTC, indicating that P-gp is the transporter mediates the intestinal efflux of cimetidine and famotidine. P-gp levels throughout the intestine were inversely related to the in vivo permeability of the drugs from the different segments. The data demonstrate that for these high-solubility low-permeability P-gp substrates, P-gp limits in vivo intestinal absorption in the distal segments of the small intestine; however P-gp plays a minimal role in the proximal intestinal segments due to significant lower P-gp expression levels in this region.

摘要

本研究的目的是探讨P-糖蛋白外排在BCS III类P-糖蛋白底物(即高溶解性低渗透性药物)体内肠道吸收过程中的作用。通过单通道肠道灌注模型,在存在或不存在P-糖蛋白抑制剂维拉帕米的情况下,测定了两种H(2)拮抗剂西咪替丁和法莫替丁在大鼠小肠不同区域的体内渗透性。在存在或不存在各种外排转运体抑制剂(维拉帕米、红霉素、奎尼丁、MK-571和烟曲霉毒素C)的情况下,研究了化合物在Caco-2细胞单层上的从顶端到基底外侧(AP-BL)以及基底外侧到顶端(BL-AP)的转运。通过免疫印迹法确认了不同肠段中P-糖蛋白的表达水平。西咪替丁和法莫替丁通过肠壁的渗透性表现出节段依赖性,与小肠近端区域相比,回肠远端的有效渗透系数(P(eff))降低。维拉帕米与药物共同灌注显著增加了回肠的渗透性,而空肠渗透性未观察到显著变化。两种药物在Caco-2细胞上的BL-AP渗透性均显著大于AP-BL渗透性,表明存在净黏膜分泌。P-糖蛋白抑制剂维拉帕米、红霉素和奎尼丁可使这种分泌呈浓度依赖性降低,而MRP2抑制剂MK-571和BCRP抑制剂FTC则无明显作用,表明P-糖蛋白是介导西咪替丁和法莫替丁肠道外排的转运体。整个肠道中的P-糖蛋白水平与不同肠段药物的体内渗透性呈负相关。数据表明,对于这些高溶解性低渗透性的P-糖蛋白底物,P-糖蛋白限制了小肠远端段的体内肠道吸收;然而,由于该区域P-糖蛋白表达水平显著较低,P-糖蛋白在小肠近端段作用极小。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验